Biocon CEO Arun Chandavarkar says Sandoz tie-up to help them target multi-billion dollar biosimilar opportunity
newsdepo.com
These biosimilars are in early stages of development. As the cost incurred during the early stages are not significant we don’t expect our Ramp;D costs to go up materially as of now.Biocon CEO Arun Chandavarkar says Sandoz tie-up to help them target multi-billion dollar biosimilar opportunity
These biosimilars are in early stages of development. As the cost incurred during the early stages are not significant we don’t expect our Ramp;D costs to go up materially as of now. Read more